Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for COVID-19-associated acute respiratory distress syndrome
IRCT20151227025726N23Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of adalimumab in coronavirus pneumonia (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Hospital discharge, Need for oxygen support and 2 more. Started Aug 2020; status: completed.
02
Drugs
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20151227025726N23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151227025726N23.